Video

Ellen Matloff on Oophorectomy Timing for BRCA Carriers

Ellen T. Matloff, MS, CGC, director, Yale Cancer Genetic Counseling Program at the Yale School of Medicine/Yale Cancer Center, discusses the proper age for a carrier of the BRCA1 or BRCA2 mutation to undergo oophorectomy.

Ellen T. Matloff, MS, CGC, director, Yale Cancer Genetic Counseling Program at the Yale School of Medicine/Yale Cancer Center, discusses the proper age for a carrier of the BRCA1 or BRCA2 mutation to undergo oophorectomy.

Recent data has been released showing that BRCA1 or BRCA2 mutation carriers who undergo an oophorectomy at age 35 have a longer life expectancy. Matloff says she was concerned with the way the data were reported because it could have appeared that 35 was a “magic age.”

In some patients, such as those with a family history of ovarian cancer that is diagnosed before age 35, it may make sense to implement risk-reduction strategies earlier on. In other patients, such as those who are not done with child bearing, it’s possible to wait.

Matloff says she recommends that all BRCA carriers discuss their mutation, personal and family history, and treatment options with a certified genetic counselor.

<<<

View more from the 2014 Miami Breast Cancer Conference

Related Videos
Cedric Pobel, MD
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.